Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Proteasome inhibitors have revolutionized outcomes in multiple myeloma, but they are used empirically, and primary and secondary resistance are emerging problems. We have identified TJP1 as a determinant of plasma cell proteasome inhibitor susceptibility. TJP1 suppressed expression of the catalytica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Zhang, Xing-Ding, Baladandayuthapani, Veerabhadran, Lin, Heather, Mulligan, George, Li, Bin, Esseltine, Dixie-Lee W., Qi, Lin, Xu, Jianliang, Hunziker, Walter, Barlogie, Bart, Usmani, Saad Z., Zhang, Qing, Crowley, John, Hoering, Antje, Shah, Jatin J., Weber, Donna M., Manasanch, Elisabet E., Thomas, Sheeba K., Li, Bing-Zong, Wang, Hui-Han, Zhang, Jiexin, Kuiatse, Isere, Tang, Jin-Le, Wang, Hua, Jin, He, Yang, Jing, Milan, Enrico, Cenci, Simone, Ma, Wen-Cai, Wang, Zhi-Qiang, Davis, Richard Eric, Yang, Lin, Orlowski, Robert Z.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4983190/
https://ncbi.nlm.nih.gov/pubmed/27132469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.03.026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados